Nuveen’s ImmunityBio IBRX Stock Holding History

Nuveen’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.53M	Sell	859,612 -19,959	-2%	-$151K	﹤0.01%	1873
2026 Q1	$6.75M	Buy	879,571 +246,477	+39%	+$1.69M	﹤0.01%	1760
2025 Q4	$1.25M	Buy	633,094 +125,134	+25%	+$284K	﹤0.01%	2503
2025 Q3	$1.25M	Buy	507,960 +76,860	+18%	+$198K	﹤0.01%	2518
2025 Q2	$1.14M	Buy	431,100 +71,431	+20%	+$192K	﹤0.01%	2546
2025 Q1	$1.08M	Buy	359,669 +4,367	+1%	+$13.2K	﹤0.01%	2612
2024 Q4	$910K	Sell	355,302 -48,226	-12%	-$201K	﹤0.01%	2753
2024 Q3	$1.5M	Hold	403,528	–	–	﹤0.01%	2564
2024 Q2	$2.55M	Sell	403,528 -102,897	-20%	-$678K	﹤0.01%	2264
2024 Q1	$2.72M	Sell	506,425 -16,052	-3%	-$72.7K	﹤0.01%	2259
2023 Q4	$2.62M	Buy	522,477 +45,198	+9%	+$142K	﹤0.01%	2289
2023 Q3	$807K	Buy	477,279 +47,554	+11%	+$95.5K	﹤0.01%	2658
2023 Q2	$1.19M	Buy	429,725 +189,140	+79%	+$535K	﹤0.01%	2585
2023 Q1	$438K	Sell	240,585 -8,313	-3%	-$25.8K	﹤0.01%	2839
2022 Q4	$3.83M	Sell	248,898 -21,085	-8%	-$116K	﹤0.01%	2069
2022 Q3	$1.34M	Sell	269,983 -3,855	-1%	-$17.6K	﹤0.01%	2601
2022 Q2	$1.02M	Sell	273,838 -4,882	-2%	-$19.6K	﹤0.01%	2770
2022 Q1	$1.56M	Sell	278,720 -169,558	-38%	-$1.04M	﹤0.01%	2626
2021 Q4	$2.73M	Buy	448,278 +181,842	+68%	+$1.37M	﹤0.01%	2408
2021 Q3	$2.6M	Sell	266,436 -311,464	-54%	-$3.43M	﹤0.01%	2548
2021 Q2	$1.73M	Buy	+577,900	New	+$9.55M	﹤0.01%	2781
2021 Q1	–	Sell	-112,537	Closed	-$1.5M	–	3385
2020 Q4	$1.5M	Sell	112,537 -731	-0.6%	-$7.03K	﹤0.01%	2645
2020 Q3	$785K	Buy	113,268 +472	+0.4%	+$4.71K	﹤0.01%	2791
2020 Q2	$1.39M	Buy	+112,796	New	+$637K	﹤0.01%	2483

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's IBRX Position: Q2 2026 in Review

Nuveen reduced its ImmunityBio (IBRX) stake by 2.3% in Q2 2026, selling an estimated $151K and leaving 859,612 shares worth $7.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1873.

Nuveen first reported a position in IBRX in Q2 2020 and has held it in 24 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Nuveen held 859,612 shares of ImmunityBio worth $7.53M as of Q2 2026.
Nuveen sold 19,959 ImmunityBio shares in Q2 2026, an estimated $151K.
ImmunityBio made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1873 holding.
Nuveen first reported a position in ImmunityBio in Q2 2020 and has held it in 24 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.